Anti-Infectives · LP-032
Ciprofloxacin Tablets
Medicine dossier. Catalogue identity is separated from unresolved product-specific fields and from external scientific references.
Development record
This dossier integrates an archived editorial source review dated 2026-09-11. Website reconciliation does not constitute a new medical or regulatory review. Controlled product approval, use instructions and supply status remain unestablished.
- Portfolio reference
- LP-032Anti-Infectives
- Generic identity
- CiprofloxacinTablet
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Layers 01–02 · Evidence boundary
What this public record establishes — and what remains held.
- Portfolio reference
- LP-032
- Generic identity
- Ciprofloxacin
- Presentation
- Tablet
- Catalogue strength
- 250 mg; 500 mg
- Catalogue pack
- Blister 10 x 10 tablets
- Public status
- Development presentation
Layer 01 · Controlled catalogue facts
- Generic identity: ciprofloxacin.
- Dosage form: tablet.
- Proposed strengths: 250 mg and 500 mg.
- General catalogue pack: blister 10 × 10 tablets.
Layer 02 · Unresolved product-specific fields
- Exact ciprofloxacin salt/hydrate basis, coating, score/divisibility and formulation.
- Strength-to-pack/SKU mapping and whether the catalogue blister presentation is controlled for each strength.
- Approved indications, age eligibility, contraindications and current fluoroquinolone risk language for the intended jurisdiction.
- Storage, shelf life, registration, manufacturing route and supply status.
02 · Variants
Preserve each catalogue row without inferring missing SKU relationships.
| Variant | Proposed strength / concentration | Dosage form | Presentation detail | Pack relationship | Evidence status |
|---|---|---|---|---|---|
| A | 250 mg | Tablet | — | Catalogue pack: blister 10 × 10 tablets; strength-specific SKU evidence not supplied | External labels/regulator warnings do not establish LP-032 approval or indication. |
| B | 500 mg | Tablet | — | Catalogue pack: blister 10 × 10 tablets; strength-specific SKU evidence not supplied | External labels/regulator warnings do not establish LP-032 approval or indication. |
The table reproduces or structures catalogue-level fields. It does not create an approved SKU, instruction or specification where the source record does not provide one.
03 · External reference context
Ingredient and dosage-form background
Ciprofloxacin is a fluoroquinolone antibiotic used for selected susceptible bacterial infections. Systemic use carries significant safety restrictions and is not a routine default when other suitable antibiotics exist. Its tablet formulation must be distinguished from ophthalmic products, which have separate use and safety information. This educational profile does not establish a Luang Pharma registration, indication, local prescribing category or product-specific benefit claim.
Clinical context and therapeutic role
Selection requires a clear bacterial indication, consideration of microbiology and resistance, and review of safer effective alternatives where appropriate. Clinical context can include particular urinary or other infections, but suitability depends on the diagnosis rather than a general category. The prescriber should evaluate tendon disease, neurologic history, myasthenia gravis, cardiovascular risk, kidney function and interacting medicines. New adverse symptoms warrant prompt review of the treatment plan.
Selected safety context
Systemic fluoroquinolones can cause serious tendon, peripheral nerve and central nervous system effects, sometimes prolonged or irreversible. Tendon pain, new numbness, weakness or significant mood or neurologic changes require urgent professional advice. Other concerns include rhythm disturbances, blood-glucose changes, severe diarrhoea and exacerbation of myasthenia gravis. Mineral supplements and antacids can affect absorption, and tizanidine is a major interaction. Severe sudden chest, back or abdominal pain requires emergency assessment.
Selected external context only. It is not a complete risk profile or Luang Pharma approved labelling. The exact authorised IFU/label and applicable professional guidance control product use.
Formulation, presentation and handling evidence
The catalogue describes a tablet presentation. The exact salt, coating, score line and release characteristics need confirmation from the authorized product information. A milligram strength identifies ingredient quantity; it does not establish whether a tablet may be split, crushed or exchanged for another formulation.
Keep the product in its labeled packaging so the batch, expiry and instructions remain identifiable. Follow the actual label for storage conditions and disposal. Do not use a damaged or unidentified tablet, and keep all medicines securely out of children’s reach.
Final instructions, storage conditions, shelf life and any after-opening/in-use limits require the exact controlled product documentation; none is created from a comparator reference.
Points for professional review
A qualified prescriber should establish the infection and need for treatment, consult current local guidance and resistance information where relevant, and select a suitable route. Generic reference literature is not a substitute for the authorized local product information.
04 · Layer 04 · Documentation gate
Controlled product documents must close the held fields.
Before this medicine record can support product-specific clinical, technical or supply claims, the exact finished-product documentation must resolve the held fields.
Finished-product specification and quantitative composition for each exact presentation.
Approved/controlled label or leaflet for the intended jurisdiction.
Strength/form-to-pack SKU matrix and controlled packaging artwork where more than one variant is listed.
Registration/market-status and manufacturing-site evidence for the exact presentation.
Editorial source check: archived record dated 2026-09-11.
Qualified product/medical review: Not recorded at B07b checkpoint
Approved Luang Pharma label: Not provided or established
Registration / availability / supply: not established by this public record.
05 · Layer 03 · Sources & review
External references are attributed, not adopted as Luang Pharma labelling.
| Source | Recorded revision / check | How it is used |
|---|---|---|
| MHRA: systemic fluoroquinolone restrictions and serious adverse effectsArchived source classification: government medicine safety update | Source revision recorded: Published 22 January 2024; Archived access check: 2026-09-11 | External reference; not Luang Pharma labelling, product approval, registration, equivalence, manufacturing evidence or supply evidence. |
| DailyMed: Ciprofloxacin tablets — official US label exampleArchived source classification: US official drug label example | Source revision recorded: Label content updated 14 May 2025; Archived access check: 2026-09-11 | External reference; not Luang Pharma labelling, product approval, registration, equivalence, manufacturing evidence or supply evidence. |
External sources may describe authorised products, public-health guidance or device classes. They do not establish equivalence, approval, model performance, manufacturing status or supply eligibility for LP-032.
Professional enquiries
Request product-specific evidence for LP-032.
State the exact presentation or configuration, organisation, destination and evidence you need. The public portfolio record is not an offer of supply.